Welcome to our dedicated page for Transuite.Org SEC filings (Ticker: TRSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Transuite.Org Inc. (TRSO) provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other Exchange Act filings. These documents explain how TRSO structures and expands its business across intelligent E-Bike charging platforms, AI-driven wellness technology, and AI ecosystem consulting, as described by the company itself.
Through its 8-K filings, TRSO details material definitive agreements such as share exchange transactions for majority interests in Goldfinch Group Co., Limited and Xirangsheng (Shenzhen) Health Technology Co., Ltd., as well as proposed acquisitions under Letters of Intent with entities like SolanAI Global Limited, SYD GOLDX PTY LTD, and Fujian Wochong Intelligent Technology Co., Ltd. The filings outline ownership structures, consideration paid in restricted common stock, and earn-out provisions tied to independent valuations.
Governance-related filings report changes in control, appointments and resignations of principal officers, and the addition of independent directors with backgrounds in financial technology, digital assets, and corporate management. Other filings describe the adoption of the 2025 Stock Incentive Plan, under which the Board may grant stock options and restricted stock awards to officers, directors, employees, and consultants.
TRSO’s Form 12b-25 notification of late filing offers narrative insight into its quarterly reporting, including references to revenue from AI-Driven Ecosystem Product Planning consulting services and significant changes in operating expenses. On this page, AI-powered tools can summarize lengthy filings, highlight key items such as business acquisitions, equity issuances, and control changes, and help readers quickly locate relevant sections within 8-K and other reports.
Transuite.Org Inc. disclosed that it has entered into and simultaneously closed a Share Exchange Agreement to acquire 100% of Xirangsheng (Shenzhen) Health Technology Co., Ltd. through its subsidiary Crestar Holdings Limited. XRS focuses on AI-powered healthcare technology built around Traditional Chinese Medicine, including AI social agents, a 21‑day health supervision system, and a large library of proprietary TCM health e‑books, with plans for an intelligent e‑commerce platform and multi‑language social media presence.
As initial consideration, Transuite.Org issued 10,000,000 restricted common shares to the seller, Hailiang Li, in an unregistered equity transaction. The agreement includes an earnout-style provision that may result in additional shares being issued based on an independent valuation of XRS and Transuite.Org’s closing share price on September 30, 2025, subject to board approval and securities law compliance.
Transuite.Org Inc. entered into a non-binding Letter of Intent on September 26, 2025 to acquire 51% of Australian licensed digital currency exchange SYD GOLDX PTY LTD through the issuance of Transuite common stock. This potential deal would give Transuite a majority equity interest in SGX if completed.
The Letter of Intent states that both parties will negotiate in good faith toward a definitive agreement, subject to due diligence, final terms, board approvals for both companies, and other customary conditions. Either party may terminate the LOI in writing if due diligence results are unsatisfactory, and the LOI explicitly states it does not create a binding obligation to close the transaction.
Transuite also issued a press release on September 26, 2025 announcing the LOI, which is furnished as an exhibit. Copies of the LOI and the press release are attached as exhibits to this report.
Transuite.Org Inc. signed a non-binding Letter of Intent to acquire 51% of the equity of Fujian Wochong Intelligent Technology Co., Ltd., a company incorporated in China, by issuing TRSO common stock. The final valuation of Wochong will be set after due diligence, and the proposed transaction depends on satisfactory due diligence, board approvals for both companies, no material adverse changes, and required third-party consents.
The LOI includes mutual confidentiality and allows either party to terminate in writing if due diligence results are unsatisfactory. It expressly states that it is not a binding commitment to complete the transaction, which remains subject to negotiation and execution of definitive agreements. Transuite also issued a press release announcing the LOI.